ZEB1 and cholangiocarcinoma: In agreement with this observation, inhibition of miR-455 abrogated the anti-tumor effects of DMY on CCA, as well as ZEB1, p-PI3K and p-AKT expression, indicating that DMY inhibits EMT in CCA through targeting the miR-455/PI3K/AKT pathway (Figure S4).